TY  - JOUR
T1  - ROsiglitazone and the case for safety over certainty
AU  - Juurlink DN
Y1  - 2010/07/28
N1  - 10.1001/jama.2010.954
JO  - JAMA
SP  - 469
EP  - 471
VL  - 304
IS  - 4
N2  - 
Approximately 10 years ago, the thiazolidinediones rosiglitazone and pioglitazone were introduced for the treatment of type 2 diabetes. Like their forerunner troglitazone, which was removed from the market following reports of hepatotoxicity, these drugs act on the gamma subtype of peroxisome proliferator-activated receptors (PPAR-γ) in the cell nucleus, resulting in heightened insulin sensitivity and improved glycemic control.1 Because insulin resistance is a common feature of type 2 diabetes, the biological effects of thiazolidinediones made these drugs appealing to patients with diabetes and to their physicians who were looking for yet another way to avoid the need for insulin. Within a few years, both drugs became multibillion-dollar products despite no direct evidence that they actually prevented the complications of diabetes.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.954
UR  - http://dx.doi.org/10.1001/jama.2010.954
ER  -